Suggested remit: To appraise the clinical and cost effectiveness of sarizotan within its marketing authorisation for the treatment of respiratory symptoms associated with Rett syndrome.
 
Status Proposed
Process STA 2018
ID number 1506

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
25 June 2020 The National Institute for Health and Care Excellence (NICE) has been asked to consider an appraisal of sarizotan for the treatment of respiratory symptoms associated with Rett syndrome. We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this proposed appraisal. The company that was developing sarizotan has advised NICE that they are no longer pursuing a licence in the UK for this product for this indication. In light of this information, NICE will not be progressing with the scoping exercise, and the workshop arranged for Tuesday 28 July 2020 has been cancelled. Please accept our apologies for any inconvenience.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance